Marker Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Marker Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 2 currently recruiting 2 completed early-phase tilt upper quartile by trial count

Marker Therapeutics: 7 sponsored US clinical trials, 2 recruiting.

Marker Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hodgkin's Lymphoma, Relapsed, Adult, with 1 trials.

Upper-quartile sponsor footprint

Marker Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 1

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

NCT06552416
RECRUITING Phase 1

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

NCT05798897
NOT YET RECRUITING Phase 1

MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

NCT06549751
TERMINATED Phase 2

Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

NCT04511130
COMPLETED NA

Plasma Adsorption in Patients With Confirmed COVID-19

NCT04358003
TERMINATED Phase 2

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

NCT02978222
COMPLETED Phase 2

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

NCT02593227

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3

Therapeutic Areas

Hodgkin's Lymphoma, Relapsed, Adult 1
Hodgkin Lymphoma, Adult 1
Non-Hodgkin Lymphoma, Relapsed 1
Non-Hodgkin Lymphoma, Refractory 1
Non-Hodgkin Lymphoma, Adult 1
MDS 1
Hodgkin Lymphoma 1
Non-Hodgkin Lymphoma 1
Acute Myeloid Leukemia, in Relapse 1
Breast Cancer 1

What is open in the Marker Therapeutics pipeline

2 recruiting of 7 indexed (29% open); 2 completed (29%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Hodgkin's Lymphoma, Relapsed, Adult (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Marker Therapeutics: open-pipeline peers nationwide

Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

Marker Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Marker Therapeutics3M4Life Research89bioAbbott Diagnostics DivisionAlabama Physical Therapy & AcupunctureAlloSourceAlnylam PharmaceuticalsAnnovis Bio
Marker Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Marker Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Marker Therapeutics page

7 registered trials is a research-attention snapshot, not an endorsement of Marker Therapeutics or any single study.

  • 2 of Marker Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hodgkin's Lymphoma, Relapsed, Adult is the condition Marker Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hodgkin's Lymphoma, Relapsed, Adult trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Marker Therapeutics pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.